SequelSEC

Axogen, Inc. AXGN

Electromedical & Electrotherapeutic Apparatus · CIK 0000805928 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$69.73M
Fiscal year ended 2026-06-30
Operating income
-$2.16M
Fiscal year ended 2026-06-30
Free cash flow
$6.33M
Fiscal year ended 2026-06-30

Axogen, Inc. (AXGN) reported revenue of $69.73M and net income of -$1.52M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Axogen, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

Axogen, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$69.73M$61.46M$59.90M$60.08M$56.66M$48.56M$49.40M$48.64M$47.91M$41.38M
Cost of revenue$19.06M$15.27M$15.50M$14.09M$14.64M$13.63M$11.83M$12.21M$12.57M$8.76M
Gross profit$50.67M$46.19M$44.41M$45.99M$42.02M$34.93M$37.58M$36.44M$35.34M$32.62M
Operating income-$2.16M-$2.83M-$9.77M$1.91M$1.67M-$1.66M$2.02M-$316.00K-$428.00K-$4.56M
Net income-$1.52M-$19.58M-$13.16M$708.00K$579.00K-$3.83M$450.00K-$1.86M-$1.92M-$6.64M
Research & development$8.59M$7.52M$12.38M$7.56M$6.85M$6.09M$6.70M$7.00M$6.66M$7.41M
Weighted-average diluted sharesshares 53.34Mshares 51.59MUnavailableshares 49.09Mshares 47.98Mshares 45.20MUnavailableshares 43.88Mshares 43.71Mshares 43.23M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0$0$0$0
Diluted EPS$-0.03$-0.38Unavailable$0.01$0.01$-0.08Unavailable$-0.04$-0.04$-0.15
Selling, general & administrative$44.24M$41.50M$41.80M$36.52M$33.49M$30.50M$28.85M$29.76M$29.12M$29.77M
General & administrative$13.41M$12.87M$14.59M$10.84M$9.69M$9.46M$8.83M$10.83M$9.42M$9.96M
Selling & marketing$30.83M$28.63M$27.21M$25.68M$23.80M$21.04M$20.02M$18.92M$19.70M$19.82M

Balance

Axogen, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$94.57M$82.65M$35.55M$23.90M$20.04M$18.10M$27.55M$18.66M$19.19M$15.71M
Total assets$304.86M$289.49M$221.69M$216.40M$205.45M$196.16M$203.73M$191.98M$188.93M$186.52M
Current assets$200.38M$184.71M$120.42M$114.46M$103.42M$93.07M$99.22M$86.25M$82.26M$78.66M
Total liabilities$48.61M$44.68M$92.84M$95.60M$93.18M$90.80M$99.82M$92.58M$93.24M$93.36M
Current liabilities$30.37M$26.01M$23.56M$28.01M$24.98M$21.74M$30.61M$23.03M$23.42M$22.93M
Total equity incl. NCI$256.26M$244.81M$128.85M$120.80M$112.28M$105.36M$103.91M$99.41M$95.69M$93.16M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$47.31M$46.07M$42.37M$40.58M$36.77M$35.50M$33.18M$29.36M$28.02M$27.64M
Accounts receivable$34.13M$28.31M$26.17M$30.78M$28.03M$26.30M$24.10M$24.63M$25.15M$24.21M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$0$0$48.39M$48.16M$47.94M$47.72M$47.50M$47.27M$47.05M$46.82M
Accounts payableUnavailableUnavailable$2.89MUnavailableUnavailableUnavailable$8.01MUnavailableUnavailableUnavailable

Cash flow

Axogen, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$7.22M$1.56M$3.04M$3.22M$7.73M-$13.18M$8.74M$3.90M$4.16M-$12.27M
Capital expenditures$893.00K$2.79M$1.25M$1.52M$722.00K$256.00K$670.00K$597.00K$910.00K$924.00K
Investing cash flow$500.00K-$15.96M$4.04M-$3.75M-$6.95M$1.34M-$813.00K-$5.00M-$1.23M-$3.25M
Financing cash flow$4.20M$59.50M$4.57M$2.39M$1.16M$2.38M$970.00K$572.00K$544.00K$204.00K
Net change in cash$11.92M$45.11M$11.65M$1.87M$1.94M-$9.46M$8.89M-$527.00K$3.48M-$15.31M
Stock-based compensation$8.77M$6.84M$16.61M$5.42M$5.17M$2.91M$3.08M$5.00M$3.91M$3.92M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.61M$1.60M$1.63M$1.64M$1.66M$1.73M$1.64M$1.65M$1.66M$1.52M

Derived

Axogen, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$6.33M-$1.22M$1.79M$1.70M$7.01M-$13.44M$8.06M$3.30M$3.26M-$13.19M
Gross margin72.7%75.2%74.1%76.6%74.2%71.9%76.1%74.9%73.8%78.8%
Operating margin-3.1%-4.6%-16.3%3.2%3.0%-3.4%4.1%-0.6%-0.9%-11.0%
FCF margin9.1%-2.0%3.0%2.8%12.4%-27.7%16.3%6.8%6.8%-31.9%
SBC / revenue12.6%11.1%27.7%9.0%9.1%6.0%6.2%10.3%8.2%9.5%
Current ratio6.60x7.10x5.11x4.09x4.14x4.28x3.24x3.74x3.51x3.43x
Revenue YoY growth23.1%26.6%21.3%23.5%18.3%17.4%15.1%17.9%25.6%12.9%
Net margin-2.2%-31.9%-22.0%1.2%1.0%-7.9%0.9%-3.8%-4.0%-16.0%
R&D / revenue12.3%12.2%20.7%12.6%12.1%12.5%13.6%14.4%13.9%17.9%
CapEx / revenue1.3%4.5%2.1%2.5%1.3%0.5%1.4%1.2%1.9%2.2%
Long-term debt / equity0.00xUnavailable0.38x0.40xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AXGN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-04-28View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.